Diffuse palmoplantar keratoderma
MONDO:0017666Palmoplantar keratoderma that diffusely involves most of the palm and sole and is caused by a genetic abnormality.
Also known as: diffuse PPK, diffuse keratosis palmoplantaris, diffuse palmoplantar hyperkeratosis
12 clinical trials for this condition and its sub-types, 0 tagged with Diffuse palmoplantar keratoderma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Diffuse palmoplantar keratoderma
-
Papillon-Lefevre disease 5 trials
-
Odonto-onycho-dermal dysplasia 2 trials
-
Bart-Pumphrey syndrome 0 trials
-
CEDNIK syndrome 0 trials
-
Clouston syndrome 0 trials
-
Haim-Munk syndrome 0 trials
-
KID syndrome 0 trials
-
Schöpf-Schulz-Passarge syndrome 0 trials
-
Dermatopathia pigmentosa reticularis 0 trials
-
Erythrokeratodermia variabilis 0 trials
8 sub-types
- Erythrokeratodermia variabilis et progressiva 1 0 trials
- Erythrokeratodermia variabilis et progressiva 2 0 trials
- Erythrokeratodermia variabilis et progressiva 3 0 trials
- Erythrokeratodermia variabilis et progressiva 4 0 trials
- Erythrokeratodermia variabilis et progressiva 5 0 trials
- Erythrokeratodermia variabilis et progressiva 6 0 trials
- Erythrokeratodermia variabilis et progressiva 7 0 trials
- Transgrediens et progrediens palmoplantar keratoderma 0 trials
-
Hearing loss with skin disease 0 trials
-
Loricrin keratoderma 0 trials
-
Mal de Meleda 0 trials
-
1 sub-type
-
Half the dose, same hope? trial tests cutting hormone therapy in prostate cancer
Disease control Recruiting nowThis phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…
Phase 3 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New combo aims to keep prostate cancer in check with lower chemo dose
Disease control Recruiting nowThis study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while redu…
Phase 2 • Sponsor: Yonghong Li • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can advanced imaging reveal hidden swallowing muscle damage in IBM?
Diagnosis Recruiting nowResearchers at Johns Hopkins University are studying whether neuromuscular ultrasound and MRI can serve as reliable markers of swallowing muscle problems in people with inclusion body myositis (IBM). The study compares imaging and clinical findings in 30 participants, including p…
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Better smiles with 3D printing? new study tests dentures for rare condition
Symptom relief Recruiting nowThis study looks at whether 3D-printed dentures fit better and make patients happier than traditional acrylic dentures in people with ectodermal dysplasia, a rare condition that affects teeth and other body parts. About 11 people aged 10 to 35 who have some remaining teeth will t…
Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Massive data bank launched to unlock secrets of ALS and motor neuron diseases
Knowledge-focused Recruiting nowThis study is building a large database of health information from 5,000 people with ALS and other motor neuron diseases. Participants share details like symptoms, test results, and disease progression during regular clinic visits. The de-identified data is then shared with resea…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New study to measure hidden toll of rare skin diseases on patients and families
Knowledge-focused Recruiting nowThis study aims to understand the full burden of 9 rare skin diseases—including physical, emotional, social, and financial challenges—on patients and their families. Researchers will use special questionnaires to track how these conditions affect daily life and care needs. About …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC